CAS 76272-56-5

Endo-9-Methyl-9-Azabicyclo [3,3,1]-Nonan-3-Amine

Description:

Endo-9-Methyl-9-Azabicyclo[3,3,1]nonan-3-amine, with the CAS number 76272-56-5, is a bicyclic amine characterized by its unique structural framework, which includes a nitrogen atom incorporated into a bicyclic system. This compound features a methyl group at the 9-position and an amine functional group at the 3-position, contributing to its reactivity and potential biological activity. The bicyclic structure provides rigidity, which can influence its interaction with biological targets, making it of interest in medicinal chemistry. The presence of the nitrogen atom in the ring system can also affect its basicity and solubility properties. Typically, compounds like this may exhibit interesting pharmacological properties, including potential use as intermediates in the synthesis of pharmaceuticals or as ligands in coordination chemistry. However, specific applications and biological activities would depend on further research and characterization. Safety and handling precautions should be observed, as with all chemical substances, due to potential toxicity or reactivity.

Formula: C₉H₁₈N₂

InChI: InChI=1/C9H18N2/c1-11-8-4-2-6-9(11,10)7-3-5-8/h8H,2-7,10H2,1H3

SMILES: CN1C2CCCC1(CCC2)N

Synonyms:

• Endo-3-Amine-9-Methyl-9-Azabicyclo[3,3,1]Nonane
• Endo-3-amino-9-methyl-9-azabicyclo[3,3,1]nonane
• Endo-9-Methyl-9-Azabicyclo[3,3,1] nonane-3-Amine
• 9-Methyl-9-Azabicyclo[3.3.1]Nonan-3-Amine
• 9-Methyl-9-Azabicyclo[3.3.1]Nonan-1-Amine
• Endo-9-methyl-9-azabicyclo[3,3,1]-nonan-3-amine
• endo-9-methyl-9-azabicyclo[3,3,1]nonan-3-amine
• 9-Methyl-9-azabicyclo[3.3.1]nonylamine
• ENDO-3-AMINE-9-METHYL-9-AZABICYCLO[3,3,1]NONAN
• Endo-9-Methyl-9-Azabicyclo-3,3,1-Nonan-3-Amine(ForGranisetronHcl)
• EMANA
• b-3-Amino-9-methyl-9-azabicyclo(3.3.1)-nonane, Granisetron Impurity E (free base)
• 1-AMINO-9-METHYL-9-AZABICYCLO[3,3,1]-NONANE
• Endo-9-Methy-9-Azabicyclo[3,31]Nonan-3-Amine
• ENDO-3-AMINE-9-METHYL-AZABICYCLO[3.3.1] NONANE
• endo-9-Methyl-9-azabicyclo[3.3.1]-3-nonylamine
• ENDO-9-METHYL-9-AZA-BICYCLO[3.3.1]NON-3-YLAMINE
• ENDO-3-AMINO-9-METHYL-9-AZABICYCLO[3.3.1]NONANE
• 9-METHYL-9-AZA-BICYCLO[3,3,1]NON-3-YL-AMINE
• Endo-9-methyl-9-azabicyclo[3,3,1] nonan-3-amine 76272-56-5
• EMANA(Endo-9-methyl-9-azabicyclo[3,3,1]-nonan-3-amine)
• -3-Amino-9-methyl-9-azabicyclo(3.3.1)-nonane, Granisetron Impurity E (free base)
• ENDO-9-METHYL-9-AZABICYCLO3,3,1-NONAN-3-AMINE
• ENDO-9-METHYL-9-AZABICYCLO[3,3,1]-NONAN-3-AMINE/EMANA

Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane

CAS: 76272-56-5

Formula: C₉H₁₈N₂

Purity: 97%

Color and Shape: Liquid

Molecular weight: 154.2526

Ref: IN-DA0034TC

(1R,3r,5S)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine

Controlled Product

CAS: 76272-56-5

Formula: C₉H₁₈N₂

Color and Shape: Neat

Molecular weight: 154.253

Ref: 86-MM0398.05

Granisetron EP Impurity E (Granisetron USP Related Compound E (Free Form))

CAS: 76272-56-5

Formula: C₉H₁₈N₂

Molecular weight: 154.26

Ref: 4Z-G-0710

endo-3-Amino-9-methyl-9-azabicyclo[3,3,1]nonane

CAS: 76272-56-5

endo-3-Amino-9-methyl-9-azabicyclo[3,3,1]nonane

Purity: ≥95%

Molecular weight: 154.25g/mol

Ref: 54-OR345616

endo-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine

Controlled Product

CAS: 76272-56-5

Impurity Granisetron EP Impurity E
Applications Granisetron impurity E. An intermediate of Granisetron.
References McCallum, R., et al.: Drugs, 36, 652 (1988), Kaumann, A., et al.: Br. J. Pharmacol., 100, 879 (1990), Mohr, K., et al.: Pharmacol. Toxicol., 70, 198 (1992), Van, W.A., et al.: Nucl. Med. Biol., 21, 41 (1994), Mize, A., et al.: Brain Res., 836, 229 (1999),

Formula: C₉H₁₈N₂

Color and Shape: Neat

Molecular weight: 154.253

Ref: TR-M288600

endo-9-Methyl-9-azabicyclo[3,3,1]nonan-3-amine

CAS: 76272-56-5

Formula: C₉H₁₈N₂

Purity: 97%

Color and Shape: Clear

Molecular weight: 154.257

Ref: 10-F036422

(3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine

CAS: 76272-56-5

Granisetron is a drug that belongs to the group of serotonin receptor antagonists. It is used as an antiemetic, mainly in the prevention and treatment of nausea and vomiting caused by cancer chemotherapy and surgery. This drug has been shown to be effective in controlling nausea and vomiting, even when given after chemotherapy or surgical procedures. Granisetron hydrochloride was synthesized in 1988 by chemists at Hoffmann-La Roche. The synthesis was patented in 1990. Potential impurities are not listed on the USP or EP pharmacopeia, but these impurities have been detected during synthesis.

Formula: C₉H₁₈N₂

Purity: Min. 95%

Molecular weight: 154.25 g/mol

Ref: 3D-IE22671

Granisetron EP Impurity E

CAS: 76272-56-5

Formula: C₉H₁₈N₂

Molecular weight: 154.26

Ref: ST-EA-CP-G16005